FBXL3: A Potential Drug Target and Biomarker (G26224)

Target Name: FBXL3

NCBI ID: G26224

FBXL3

FBXL3: A Potential Drug Target and Biomarker

The F-box/LRR-repeat protein 3A (FBXL3) is a protein that is expressed in various tissues and cell types throughout the body. It is a key regulator of cell proliferation and has been implicated in the development and progression of various diseases, including cancer. In this article, we will discuss the potential drug target and biomarker properties of FBXL3, as well as its current research and development status.

Potential Drug Target

FBXL3 is a protein that can interact with various drug targets, including tyrosine kinase receptor (TKR) and tyrosine phosphorylase (TPL) systems. These interactions make FBXL3 a potential drug target for the treatment of various diseases, including cancer.

One of the FBXL3-TKR interactions is known as the \"FBXL3-TKR signaling pathway.\" This pathway is involved in the regulation of cell proliferation and has been implicated in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. FBXL3 has been shown to play a negative role in the regulation of TKR signaling, which can lead to the inhibition of cell proliferation and the development of cancer.

In addition to its role in TKR signaling, FBXL3 has also been shown to interact with TPL signaling systems. The TPL signaling pathway is involved in the regulation of cell growth and has been implicated in the development and progression of various diseases, including cancer. FBXL3 has been shown to play a positive role in the regulation of TPL signaling, which can lead to the stimulation of cell growth and the development of cancer.

Biomarker

FBXL3 has also been shown to serve as a potential biomarker for the diagnosis and prognosis of various diseases, including cancer. FBXL3 has also been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that FBXL3 levels are often elevated in cancer tissues compared to non-cancerous tissues.

FBXL3 has also been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer. By regulating the cell cycle, FBXL3 has been shown to contribute to the development of a more aggressive and invasive form of cancer.

Current Research and Development Status

FBXL3 is currently being targeted by researchers for the development of new drugs as a potential drug target for the treatment of various diseases, including cancer. There are several ongoing clinical trials that are focused on the use of FBXL3 as a drug target.

One of the most promising FBXL3-targeted drugs is a small molecule inhibitor called FBXL31, which is being developed by InSight Pharmaceuticals. FBXL31 is shown to inhibit the interaction between FBXL3 and TKR, which can lead to the inhibition of cell proliferation and the development of cancer.

Another promising FBXL3-targeted drug is a monoclonal antibody called ACI-3023, which is being developed by AstraZeneca. ACI-3023 is shown to selectively bind to FBXL3 and inhibit its interaction with TKR, which can lead to the inhibition of cell proliferation and the development of cancer.

Conclusion

FBXL3 is a protein that has the potential to be a drug target for the treatment of various diseases, including cancer. Its interactions with TKR and TPL signaling systems make it a potential target for the inhibition of cell proliferation and the development of cancer. FBXL3 has has also been shown to serve as a potential biomarker for the diagnosis and prognosis of various diseases, including cancer.

Currently, research on FBXL3 as a drug to treat cancer and other diseases is still in its preliminary stages. Nonetheless, FBXL3 remains highly promising for its role in inhibiting cell proliferation and cancer development due to its interaction with TKR and TPL signaling pathways and as a potential drug target.

Protein Name: F-box And Leucine Rich Repeat Protein 3

Functions: Substrate-recognition component of the SCF(FBXL3) E3 ubiquitin ligase complex involved in circadian rhythm function. Plays a key role in the maintenance of both the speed and the robustness of the circadian clock oscillation (PubMed:17463251, PubMed:23452855, PubMed:27565346). The SCF(FBXL3) complex mainly acts in the nucleus and mediates ubiquitination and subsequent degradation of CRY1 and CRY2 (PubMed:17463251, PubMed:23452855, PubMed:27565346). Activity of the SCF(FBXL3) complex is counteracted by the SCF(FBXL21) complex (PubMed:23452855)

The "FBXL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets